This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any compound.
What Is MK-677?
MK-677, also known as ibutamoren or ibutamoren mesylate, is a non-peptide growth hormone secretagogue that is orally active. Developed by Merck, it is technically not a peptide but a small molecule ghrelin mimetic — it binds to the same growth hormone secretagogue receptor (GHS-R1a) that ghrelin targets. Its oral bioavailability distinguishes it from injectable secretagogues like ipamorelin and GHRP-6, making it the most accessible GH-elevating compound in the research space.
Despite reaching Phase II clinical trials for multiple indications including growth hormone deficiency, sarcopenia, and hip fracture recovery, MK-677 has never received FDA approval. It is classified as an investigational drug and is also on WADA's prohibited list for athletes.
Mechanism of Action
MK-677's mechanism involves several interconnected pathways:
- Ghrelin receptor agonism: Binds to GHS-R1a receptors in the pituitary and hypothalamus, stimulating GH release. Unlike injectable peptides with short half-lives, MK-677's 24-hour active duration creates sustained GH and IGF-1 elevation.
- Somatostatin suppression: Reduces somatostatin signaling, which normally inhibits GH release, resulting in an amplified secretory response.
- IGF-1 elevation: Studies by Copinschi et al. (1997) showed that 25 mg daily for 7 days increased 24-hour GH secretion by 97% and IGF-1 by 55% in young subjects. In elderly subjects, 2 months of treatment restored IGF-1 levels to young-adult ranges.
- Appetite stimulation: As a ghrelin mimetic, MK-677 strongly activates hunger pathways. This is one of its most pronounced effects and can be either beneficial (for underweight populations) or problematic (for those managing body composition).
Clinical Research Findings
Multiple clinical studies have characterized MK-677's effects. Murphy et al. (1998) demonstrated that 12 months of 25 mg daily treatment in healthy older adults increased GH and IGF-1 to levels typical of younger adults, with modest increases in fat-free mass. Nass et al. (2008) showed sustained IGF-1 elevation over 2 years without tachyphylaxis — GH levels remained elevated without evidence of receptor desensitization.
Sleep studies reveal that MK-677 increases Stage IV (slow-wave) sleep duration by approximately 50% and REM sleep by 20%, likely mediated by GH's role in sleep architecture. This is one of the most consistently reported benefits in both clinical and anecdotal settings.
Side Effects and Safety Concerns
MK-677's side effect profile reflects its sustained GH and ghrelin-mimetic activity:
- Increased appetite (significant and persistent in most users)
- Water retention and peripheral edema
- Elevated fasting blood glucose and insulin resistance (a key concern with chronic use)
- Lethargy and fatigue, particularly during initial use
- Tingling and numbness in extremities (carpal tunnel-like symptoms)
The insulin resistance concern is the most clinically significant. A 2-year study in elderly subjects showed deterioration in fasting glucose and HbA1c, particularly in those with pre-existing metabolic risk factors. Blood glucose monitoring is essential during MK-677 use.
The Bottom Line
MK-677 offers the unique advantage of oral GH secretagogue activity with sustained 24-hour elevation of GH and IGF-1. Its sleep-enhancing effects are well-documented and its convenience is unmatched in the secretagogue category. However, the metabolic trade-offs — particularly insulin resistance and appetite stimulation — require careful consideration and monitoring. It remains investigational and is not approved for any clinical indication.